Free tool
FAERS Monitor: Casodex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022310 or its brand name (Casodex, Bicalutamide). Reports on generic versions are filed under their own applications.
Reports
15,314
Serious
12,703
83% of reports
Hospitalization
5,517
Death reported
2,753
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,344
- death1,010
- prostatic specific antigen increased951
- asthenia819
- hot flush804
- prostate cancer757
- malignant neoplasm progression725
- drug ineffective613
- dizziness590
- nausea569
- dyspnoea553
- diarrhoea537
- decreased appetite521
- anaemia506
- metastases to bone434
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 224 |
| 2005 | 268 |
| 2006 | 264 |
| 2007 | 235 |
| 2008 | 483 |
| 2009 | 606 |
| 2010 | 505 |
| 2011 | 469 |
| 2012 | 433 |
| 2013 | 560 |
| 2014 | 651 |
| 2015 | 884 |
| 2016 | 1,115 |
| 2017 | 1,170 |
| 2018 | 1,305 |
| 2019 | 1,011 |
| 2020 | 870 |
| 2021 | 890 |
| 2022 | 944 |
| 2023 | 693 |
| 2024 | 631 |
| 2025 | 735 |
| 2026 | 368 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,845 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prostatic specific antigen increasedSignal | 951 | 101.8 | 95.5 | 88,296 |
| metastases to boneSignal | 434 | 37.3 | 33.9 | 14,892 |
| hot flushSignal | 804 | 14.8 | 13.8 | 10,257 |
| prostate cancerSignal | 757 | 13.0 | 12.2 | 8,356 |
| malignant neoplasm progressionSignal | 725 | 9.8 | 9.1 | 5,697 |
| anaemiaSignal | 506 | 3.7 | 3.4 | 978 |
| decreased appetiteSignal | 521 | 3.1 | 2.8 | 739 |
| astheniaSignal | 819 | 3.0 | 2.8 | 1,104 |
| fatigueSignal | 1,344 | 2.4 | 2.3 | 1,106 |
| dizziness | 590 | 1.6 | 1.5 | 145 |
| death | 1,010 | 1.6 | 1.5 | 243 |
| dyspnoea | 553 | 1.3 | 1.2 | 49 |
| diarrhoea | 537 | 1.1 | 1.1 | 10 |
| nausea | 569 | 1.0 | 0.9 | 0 |
| drug ineffective | 613 | 0.6 | 0.6 | 133 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.